Liraglutide vs Semaglutide
A side-by-side research comparison of Liraglutide and Semaglutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Liraglutide | Semaglutide |
|---|---|---|
| Full name | Liraglutide (GLP-1 Receptor Agonist / Saxenda) | Semaglutide (GLP-1 Receptor Agonist) |
| Category | Weight Management | Weight Management |
| Status | FDA Approved | FDA Approved |
| Mechanism | Binds and activates the GLP-1 receptor, enhancing glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite through hypothalamic signaling. | Binds GLP-1 receptors in the pancreas to stimulate insulin secretion, in the brain to reduce appetite, and in the GI tract to slow gastric emptying. 94% homology to native GLP-1. |
| Molecular weight | 3,751 Da | 4,114 Da |
| Half-life | 13 hours | 7 days (168 hours) |
| Bioavailability | ~55% (subcutaneous) | High (SubQ ~89%), Moderate (oral ~1% with SNAC) |
| Typical dose | 0.6-3.0 mg | 0.25 mg → titrate up to 2.4 mg |
| Frequency | Once daily | Once weekly |
| Route | Subcutaneous | Subcutaneous injection |
Liraglutide reported benefits
- Proven weight loss (5-10%)
- Long safety track record
- Cardiovascular benefit
- Improved glycemic control
- Reduced food intake
Semaglutide reported benefits
- Significant weight loss (15-17%)
- Improved glycemic control
- Cardiovascular risk reduction
- Reduced food cravings
- Lower HbA1c
Related comparisons
Research and educational reference only. Not medical advice.